In midlife, lower Aβ42:Aβ40 ratio was associated with increased risk of incident all-cause dementia over 6-7 years of follow-up (HR 1.11 per SD lower).

Clinical Score: 0.500 Price: $0.50 Alzheimer's disease human Status: extracted

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting N/A in human. Primary outcome: In midlife, lower Aβ42:Aβ40 ratio was associated with increased risk of incident all-cause dementia

Description

Plasma biomarkers measured using Quanterix Simoa platform from stored specimens; dementia ascertained by neuropsychological assessment, participant contact, and medical record surveillance

TARGET GENE

N/A

MODEL SYSTEM

human

ESTIMATED COST

TIMELINE

0 months

PATHWAY

amyloid-beta metabolism

SOURCE

pmid_39068543

PRIMARY OUTCOME

In midlife, lower Aβ42:Aβ40 ratio was associated with increased risk of incident all-cause dementia over 6-7 years of follow-up (HR 1.11 per SD lower).

Scoring Dimensions

Related Hypotheses (1)

XOR+ stress-responsive astrocytes represent a novel AD-associated cell state linking oxidative stres0.380

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.